Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The analyst consensus as of May 2026 leans bullish, with 8 Buys, 3 Outperforms, and 7 Holds across 15 analysts covering RMD
We can see at least three disadvantages
Semaglutide is the GLP-1-only option in this group, commonly used as the baseline comparison when people talk about newer dual or triple agonists
According to the FDA prescribing information, nausea occurred in 12-24% of patients, diarrhea in 11-17%, vomiting in 5-10%, and constipation in 5-7%, with rates varying by dose
US$ 27.32
US$ 25.13
US$ 25.13
US$ 24.40
US$ 26.94
US$ 20.51
US$ 23.45
US$ 22.66
US$ 24.64
US$ 20.84
US$ 28.25
US$ 24.19
US$ 29.35
US$ 21.70
US$ 27.70
US$ 29.00
US$ 23.11
